The inflammatory bowel disease questionnaire: A valid and reliable measure in ulcerative colitis patients in the north east of England

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 9, 1998, Pages 961-966

  Han, S W ^a   Mccoll, E ^b   Steen, N ^b   Barton, J R ^b   Welfare, M R ^b  

^a NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Health related quality of life; Inflammatory Bowel Disease Questionnaire; Short Form 36 Health Survey; Ulcerative colitis

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; ENTERITIS; FEMALE; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; SCORING SYSTEM; ULCERATIVE COLITIS; UNITED KINGDOM; VALIDATION PROCESS;

AGE FACTORS; COLITIS, ULCERATIVE; ENGLAND; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEX FACTORS;

EID: 0031655587     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655298750026994     Document Type: Article

References (38)

1. Mallett SJ, Lennard-Jones JE, Bingley J, Gillon E. Living with disease. Colitis. Lancet 1978;2:619-21.
2. Kjeldsen J, Schaffalitzky de Muckadell OB. Review: assessment of disease severity and activity in inflammatory bowel disease. Scand J Gastroenterol 1993;28:1-9.
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2:1041-8.
4. Talstad I, Gjone E. The disease activity of ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1976;11:403-8.
5. Powell-Tuck J, Brown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833-7.
6. Cooke WT, Prior P. Determining disease activity in inflammatory bowel disease. J Clin Gastroenterol 1984;6:17-25.
7. Kambe H, Yoshida T, Haraguchi Y, Iwashita T, Sakamoto A, Tanaka K. Quantification of disease activity in patients with ulcerative colitis. J Clin Gastroenterol 1986;8:651-4.
8. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
9. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler J, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
10. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27 Suppl 3:S217-32.
11. Mitchell A, Guyatt G, Singer J, Irvine EJ, Goodacre R, Tompkins C, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988;10:306-10.
12. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
13. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992;14:15-9.
14. Irvine EJ. A quality of life index tor inflammatory bowel disease. Can J Gastroenterol 1993;7:155-9.
15. Irvine EJ. Quality of life - rationale and methods for developing a disease-specific instrument for inflammatory bowel disease. Scand J Gastroenterol 1993;28 Suppl 199:22-7.
16. Irvine EJ. Quality of life-measurement in inflammatory bowel disease. Scand J Gastroenterol 1993;28 Suppl 199:36-9.
17. Irvine EJ. Quality of life in inflammatory bowel disease: biases and other factors affecting scores. Scand J Gastroenterol 1995; 30 Suppl 208:136-40.
18. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
19. Irvine EJ, Feagan BG, Wong CJ. Does self-administration of a quality of life index for inflammatory bowel disease change the results? J Clin Epidemiol 1996;49:1177-85.
20. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br Med J 1992;305:160-4.
21. Garrat AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF-36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? Br Med J 1993;306: 1440-4.
22. Jenkinson C, Coulter A, Wright L. Short Form-36 (SF-36) health survey questionnaire: normative data for adults of working age. Br Med J 1993;306:1437-40.
23. Ware JE. Editorial: Measuring patients' views: the optimum outcome measure. Br Med J 1993;306:1429-30.
24. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
25. McHorney CA, Ware JE, Raczek AE. The MOS 36-item Short Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
26. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ. Validating the SF-36 Health Survey Questionnaire in patients with psoriatic arthritis. J Rheumatol 1997;24:511-7.
27. Chren M, Lasek RJ, Quinn LM, Covinsky KE. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol 1997;108:103-7.
28. Bowling A. Measuring disease. A review of disease-specific quality of life measurement scales. Buckingham, UK: Open University Press; 1995.
29. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;22:293-6.
30. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991;12:142S-58S.
31. de Boer AGEM, Wijker W, Bartelsman JFW, de Haes HCJM. Inflammatory Bowel Disease Questionnaire: cross-cultural adaptation and further validation. Eur J Gastro Hepat 1995;7: 1043-50.
32. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. Am J Gastroenterol 1996;91:1571-8.
33. Martin F, Sutherland L, Beck IT, Anderson AH, Williams CN, Saibil F, et al. Oral 5-ASA versus prednisolone in short term treatment of Crohn's disease. A multicentre controlled trial. Can J Gastroenterol 1990;4:452-7.
34. Feagan B, McDonald JWD, Rochon J, Laupacis A, Fedorak RN, Kinnear D, et al. Chronic low dose cyclosporine in the treatment of Crohn's disease. N Engl J Med 1994;330:1846-51.
35. Greenberg GR, Feagan BG, Martin FM, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
36. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
37. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
38. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.